logo

Liminal Biosciences Inc. (LMNL)



Trade LMNL now with
  Date
  Headline
9/8/2020 6:05:26 AM Liminal BioSciences Announces Resubmission Of BLA For Ryplazim For Treatment Of Congenital Plasminogen Deficiency
1/13/2020 7:00:00 AM Liminal BioSciences Outlines Corporate Priorities for 2020 (Press Release)
6/14/2019 3:34:30 AM Prometic Announces Four Abstracts Highlighting Progress In Developing PBI-4050
12/19/2018 7:32:29 AM Prometic Life Sciences Names Simon Best As Interim CEO; Pierre Laurin Has Stepped Down
8/7/2018 7:13:14 AM Prometic Receives Rare Pediatric Disease Designation From FDA For Small Molecule Drug Candidate, PBI-4050
4/30/2018 6:33:39 AM Prometic Reports Positive Clinical Data From IVIG Pivotal Phase 3 Trial; Meets Primary And Secondary Endpoints
4/12/2018 6:34:22 AM Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial
3/5/2018 7:09:40 AM Prometic: FDA Grants Rare Pediatric Disease Designation To Inter-Alpha-Inhibitor-Proteins For Necrotizing Enterocolitis
2/16/2018 7:33:17 AM Prometic Announces Publication Of PBI-4050's Novel Antifibrotic Mechanism Of Action In American Journal Of Pathology
7/30/2015 9:17:08 AM RBC Capital Markets Initiates ProMetic Life Sciences Inc. (PLI.TO) At Outperform With C$3.50 Price Target